TissueCypher® is the first diagnostic test of its kind that predicts the risk of developing esophageal cancer in patients with Barrett’s Esophagus.
Barrett's Esophagus & Esophageal Cancer
Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn howNews
View All News
06/25/2020
Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE... Read More
03/3/2020
Cernostics Announces Groundbreaking Data Demonstrating TissueCypher® Performance for Predicting Risk of Progression to EAC in Patients with Non-Dysplastic BE... Read More
10/22/2019
TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences... Read More
Events
01/09/2017 — San Francisco, CA
JP Morgan Healthcare Conference
05/06/2017 — Chicago, IL
Digestive Disease Week
10/13/2017 — Orlando, FL
American College of Gastroenterology
